Clinical observation of docetaxel combined with cisplatin in treatment of advanced non-small cell lung cancer
GUO Xiaoying1, SHEN Guohong2,SUN Changyon1, LI Ying3, GENG Li2
1.Department of Pharmacy, 2.Department of Oncology, 3.Department of Medicine,Shanxi Provincial Crops Hospital, Chinese People’s Armed Police Forces, Taiyuan 030006, China
Abstract:Objective To study the efficacy and toxicities of docetaxel combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods 214 patients with advanced NSCLC confirmed pathlogically and/or cytologically from May 2012 to May 2014 were divided into two groups, group one (n=79) received first-line chemotherapy, the other group (group two, n=135) received second-line chemotherapy. The two groups were given docetaxel 75 mg/m2, D1; plus cisplatin 80 mg/m2, D1-3. The process was repeated every 3 weeks. The efficacy and toxicities were assessed after 2 cycles. Results The total efficacy was 25.23%. The two groups had no CR patient. The effective rate in the two groups were 31.64% and 21.48% respectively (P=0.283). The major toxicity was myelosuppression, nausea and vomiting. The III/IV° myelosuppression was 10.75%. The serious reduction rates of platelets in the two groups were 2.53% and 8.15%, respectively(P<0.05). There was no other obviously different side effects in the two groups. Conclusions The combined chemotherapy of docetaxel with cisplatin is effective in the treatment of advanced NSCLC patient,especially in liver metastasis, and toxicities are tolerable.
Raez L E, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer [J]. Curr Opin Oncol, 2006, 18(2): 156-161.
[6]
Puglisi F, Barbone F, Tell G, et al. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas [J]. Oncol Rep, 2002, 9(1):11-18.
[7]
Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regiments for advanced non-small cell lung cancer [J]. N Engl Med, 2002, 346: 92-98.